NIAAA Medications Development Data Coordinating Center

药物疗法在治疗酒精依赖和酒精相关疾病方面有很大的希望，并为更广泛的酒精依赖者提供更多的治疗选择。NIAAA的一个主要优先事项是促进药物的发现，开发和提供，以治疗酒精使用障碍和酒精相关的医学疾病。为了加快药物开发过程中的先导化合物，NIAAA建立了一个2期临床试验计划，即NIAAA临床研究小组（NCIG），以证明药物的初步有效性。该合同的目的是为NCIG建立一个数据协调中心，以进行使用新药候选药物治疗酒精使用障碍的多中心临床试验的各个方面。

Pharamacotherapy holds much promise for treating alcohol dependence and alcohol-related disorders, and for offering more treatment options to a wider spectrum of alcohol dependent individuals. A major priority of NIAAA is to facilitate the discovery, development, and delivery of medications to treat alcohol use disorders and alcohol-related medical disorders. To accelerate lead compounds in the drug development process, NIAAA has established a Phase 2 clinical trials program, the NIAAA Clinical Investigations Group (NCIG), to demonstrate the preliminary effectiveness of medications. The purpose of this contract is to establish a Data Coordinating Center for the NCIG to conduct all aspects of multi-center clinical trials for the treatment of alcohol use disorders using novel drug candidates.